(NASDAQ: NLSP) NLS PHARMACEUTICALS is trending up this pre-market on recent positive clinical trials news.

(NASDAQ: NLSP) NLS PHARMACEUTICALS is trending up this pre-market on recent positive clinical trials news.

NLS Pharmaceutics Achieves 90% Enrollment Milestone in Quilience(R) Phase 2a Clinical Trial for Patients with Narcolepsy

  • Since the interim results were released in March, patient enrollment has nearly doubled
  • Of the 60 patients planned for the study, 54 have now been randomized with several others currently undergoing screening
  • Nearly 90% of patients that completed the Phase 2a trial to date have rolled over into the open label extension (OLE) study
  • Patients in the OLE study (both NT1 and NT2) remain on Quilience monotherapy, without any additional stimulant, wake promoting nor anti-cataplectic treatment, with several on therapy for over 5 months

ZURICH, SWITZERLAND / ACCESSWIRE / May 4, 2022 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that 90% of the 60 patients required to complete its Phase 2a clinical trial for Quilience (Mazindol ER) have been randomized and the Company continues to expect to report final results from this ground-breaking trial by mid-Q3 2022.

Read entire article here: https://www.accesswire.com/700091/NLS-Pharmaceutics-Achieves-90-Enrollment-Milestone-in-QuilienceR-Phase-2a-Clinical-Trial-for-Patients-with-Narcolepsy

JOIN OUR NEWSLETTER

Signup today for free and be the first to get notified of breaking news.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist